{"id":117758,"date":"2026-08-20T07:09:12","date_gmt":"2026-08-20T07:09:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/117758\/"},"modified":"2026-08-20T07:09:12","modified_gmt":"2026-08-20T07:09:12","slug":"novartis-swxnovn-lines-up-pivotal-cardiovascular-data-for-esc-2026","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/117758\/","title":{"rendered":"Novartis (SWX:NOVN) Lines Up Pivotal Cardiovascular Data For ESC 2026"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide. <\/p>\n

Novartis (SWX:NOVN) plans to present late breaking data from multiple pivotal cardiovascular studies at the 2026 European Society of Cardiology Congress. <\/p>\n

The presentations include head to head Phase IV results for Leqvio in LDL C management. <\/p>\n

New analyses on bleeding risk for abelacimab in atrial fibrillation are also scheduled for the ESC 2026 program. <\/p>\n

These data may influence future treatment guidelines and physician use of Novartis cardiovascular therapies. <\/p>\n

Investors watching how large drugmakers use fresh clinical evidence to shape adoption trends in key disease areas may also want to review a broader basket of high quality undervalued stocks through 270 high quality undervalued stocks<\/a>. <\/p>\n

\"SWX:NOVN<\/a> SWX:NOVN Earnings & Revenue Growth as at Aug 2026 <\/p>\n

Novartis is a large pharmaceuticals company with a CHF241.6 billion market cap that researches, develops, manufactures, and sells medicines across Switzerland and international markets. As a result, any high profile cardiovascular data at ESC 2026 feeds directly into one of its core therapy areas. <\/p>\n

We’ve flagged 1 risk for Novartis. See which could impact your investment.<\/a> <\/p>\n

Cardiology data loadout tilts Novartis more to the opportunity side than the risk side <\/p>\n

For investors, this ESC 2026 slate gives Novartis several shots at reinforcing its position in high value cardiovascular segments. Clear efficacy and convenience data for Leqvio in VICTORION-CHALLENGE and VICTORION-Difference would support the idea that Novartis can win share in LDL C management against oral options. A cleaner bleeding profile for abelacimab in atrial fibrillation could add another differentiated asset in a large market. The company already carries a high level of debt, so stronger medium term product traction is important. On balance, this news leans more toward supporting the opportunity case than the risk case, although the data still need to deliver. <\/p>\n

The key checkpoint now is the actual ESC 2026 readouts. Investors will want to see whether Leqvio meets LDL C targets versus bempedoic acid and whether AZALEA TIMI 71 shows a meaningfully different total bleeding pattern for abelacimab compared with rivaroxaban. Those two data sets will go a long way to confirming or challenging the stronger cardiovascular thesis for Novartis. <\/p>\n

For the full picture including more risks and rewards, check out the complete Novartis analysis<\/a>. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVN.SW<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":117759,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[57304,17760,206],"class_list":["post-117758","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-2026-european-society-of-cardiology-congress","tag-atrial-fibrillation","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117126585796675150","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/117758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=117758"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/117758\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/117759"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=117758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=117758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=117758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}